MKT Capital Applauds Aurinia Pharmaceuticals’ Management Transition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
MKT Capital Applauds Aurinia Pharmaceuticals’ Management Transition
March 23, 2026 11:00 AM EDTBelieves the Boards Decision to Remove CEO Peter Greenleaf and Install Kevin Tang as CEO Validates Multi-Year Shareholder Campaign
Commends New Leaderships Commitment to Shareholder Alignment Through Zero CEO Compensation
Expects Aurinia to Enter New Chapter of Disciplined Capital Allocation and Value Creation
CAYMAN ISLANDS--(BUSINESS WIRE)-- MKT Capital Ltd. (together with its affiliates, MKT Capital or we), a significant long-term shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today issued the following statement in response to the Companys announcement... More
